DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fosamax Plus D (Alendronate Sodium / Cholecalciferol) - Published Studies


Fosamax Plus D Related Published Studies

Well-designed clinical trials related to Fosamax Plus D (Alendronate / Cholecalciferol)

Effect of alendronate and vitamin D on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. [2011.08]

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. [2011.06]

Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. [2011.06]

Alendronate reduces osteoclast precursors in osteoporosis. [2010.10]

Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. [2009.04]

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. [2009.02.15]

Alendronate is effective to treat bone loss in renal transplantation recipients. [2008.12]

A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. [2008.12]

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. [2008.11]

Alendronate/vitamin D(3) 70 mg/2800 IU with and without additional 2800 IU vitamin D(3) for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial. [2008.05.15]

Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. [2008.01]

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. [2008]

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. [2007.11.30]

Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. [2007.06]

Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. [2007.05]

Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. [2007.05]

Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). [2007.03]

Effects of a combined alendronate and calcitriol agent (Maxmarvil(R)) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. [2006.12]

Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. [2006.09]

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. [2006.08.17]

Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. [2006.03]

Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. [2006]

Daily and cyclic parathyroid hormone in women receiving alendronate. [2005.08.11]

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. [2004.09]

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. [2004.03]

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. [2004.02.19]

Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. [2004.02]

Efficacy of alendronate in adults with cystic fibrosis with low bone density. [2004.01.01]

Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. [2003.11.27]

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. [2003.05]

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. [2002.10]

Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. [2002.04]

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. [2002.03]

Alendronate prevents further bone loss in renal transplant recipients. [2001.11]

A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. [2000]

A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. [1999]

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. [1998.12.23]

Well-designed clinical trials possibly related to Fosamax Plus D (Alendronate / Cholecalciferol)

[Frontiers in Vitamin D ; Basic Research and Clinical Application. Effect of active vitamin D(3) on osteoporosis]. [2011.11]

Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. [2006.03.15]

The effect of hormone replacement on physical performance in community-dwelling elderly women. [2005.11]

BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. [2005.08]

A prospective randomized study for prevention of postrenal transplantation bone loss. [2005.05]

Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. [2004.08]

Bisphosphonates in the treatment of thalassemia-induced osteoporosis. [2002.08]

What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? [2001.06]

Other research related to Fosamax Plus D (Alendronate / Cholecalciferol)

Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3. [2012]

Femoral strength in osteoporotic women treated with teriparatide or alendronate. [2011.10.17]

Effect of alendronate on early bone loss of renal transplant recipients. [2011.03]

Alendronate reduces osteoclast precursors in osteoporosis. [2010]

Vitamin D insufficiency does not affect response of bone mineral density to alendronate. [2009.07]

Effect of alendronate in elderly patients after low trauma hip fracture repair. [2009.06]

Additional beneficial effects of recombinant growth hormone in alendronate-treated patients with idiopathic osteoporosis. [2009]

Effects of alendronate and alfacalcidol on the femoral bone mass and bone strength in orchidectomized rats. [2008.12.31]

Vitamin D insufficiency does not affect response of bone mineral density to alendronate. [2008.11.29]

Effect of alendronate in elderly patients after low trauma hip fracture repair. [2008.10.28]

Calcium, vitamin D supplements with or without alendronate and supragingival calculus formation in osteoporotic women: a preliminary study. [2008.08]

The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. [2008.06]

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. [2008.03]

Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. [2008.02]

Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. [2008.02]

The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. [2007.09]

Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats. [2007.03]

Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women. [2007.02]

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. [2005.06]

Alendronate for treatment of renal transplant patients with osteoporosis. [2003.06]

Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. [2002.10]

Calcitriol and alendronate combination treatment in menopausal women with low bone mass. [1999]

A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. [1998.08]

Other possibly related research studies

79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. [2007.08]

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. [2007.12]

Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. [2007.04]

Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. [2007.06]

[Current research in adequate treatment by Osteoporosis Research Group] [2006.09]

[Protocol for prevention and treatment of osteoporosis in patients with cystic fibrosis] [2005.09.17]

Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin? [2005]

Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. [2004.06]

7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. [2004.03.15]

A comprehensive review of treatments for postmenopausal osteoporosis. [2003.01]

Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. [2001.10]

[Costs of different intervention strategies to prevent hip fractures] [1999.08.02]

Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. [1999.03]

Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. [2007.06]

[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis] [2007.04]

Effect of vitamin D-containing plant extracts on osteoporotic bone. [2007.03]

1Alpha,25-dihydroxy-2beta(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora. [2007.01]

Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. [2008.04]

Potential of alfacalcidol for reducing increased risk of falls and fractures. [2009.01.22]

Potential of alfacalcidol for reducing increased risk of falls and fractures. [2009.08]

[Economics of medicament therapies for osteoporosis] [2009.05]

[A-TOP research group/JOINT program] [2009.05]

[Drug therapy of secondary osteoporosis: glucocorticoid-induced osteoporosis] [2009.05]

A brown tumor after biliopancreatic diversion for severe obesity. [2009.04]

[New development in bisphosphonate treatment. Fracture prevention by bisphosphonates] [2009.01]

Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting. [2010.06]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017